Impact of human immunodeficiency virus on category I pulmonary tuberculosis cases in a tertiary care hospital: a case control study


  • Monali Kadam Department of Community Medicine, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India



HIV-AIDS, Treatment outcome, Tuberculosis


Background: Tuberculosis (TB) is an opportunistic infection (OI). OIs are infections that occur more often or are more severe in people with weakened immune systems than in people with healthy immune systems. Human immunodeficiency virus (HIV) weakens the immune system, increasing the risk of TB in people with HIV. This case control study was done to assess the impact of HIV on clinical aspects and treatment outcome of newly diagnosed bacteriologically positive pulmonary tuberculosis.

Methods: This study was done among unmatched 75 cases and 75 controls who were pulmonary TB and TBHIV co-infected patients. Data were collected using a pretested, structured, interviewer-administered questionnaire and was analyzed using descriptive and analytical statistics.

Results: Total 150 patients were enrolled in the study out of which 75 patients had HIV-TB co-infection while remaining 75 patients were diagnosed as pulmonary TB. Treatment success rates are 74.7 % (56/75) for TB-HIV co-infected patients and 82.7% (62/75) for pulmonary TB patients. TB-HIV co-infected patients had a higher risk of an unsuccessful treatment outcome [(p = 0.232) with OR and 95% CI of 0.68 (0.28-1.36)]. The risk of unsuccessful treatment outcome was associated with family history of TB, Tobacco use, low BMI.

Conclusions: TB treatment success rate is good as compared to the WHO minimum requirement. Successful treatment outcome is lower among patients with HIV infection, tobacco use, low BMI, <200 /mm3 CD4 count patients. Therefore, due emphasis should be given to these high-risk groups.


WHO World Health Organization Tuberculosis, 2021. Available at: Accessed 21 June 2023.

Centers for Disease Control and Prevention. Tuberculosis (TB) - World TB Day - History, 2021. Available at: history.htm. Accessed 21 June 2023.

World Health Organisation. Global Tuberculosis report 2021. Available at: iris/bitstream/handle/10665/336069/9789240013131-eng.pdf. Accessed 21 June 2023. India M. India TB Report 2022: Ministry of Health and Family Welfare, 2022. Available at: ?lid=3538. Accessed 21 June 2023. Global HIV & AIDS statistics-2020 fact sheet. Available at: resources/fact-sheet. Accessed 21 June 2023.

Kamath R, Sharma V, Pattanshetty S, Hegde MB, Chandrasekaran V. HIV-TB coinfection: Clinico-epidemiological determinants at an antiretroviral therapy center in Southern India. Lung India: official organ of Indian Chest Society. 2013;30(4):302.

Unnikrishnan B, Holla R, Darshan BB, Arjun BY, Thapar R, Mithra P, et al. Clinico epidemiological profile of HIV-TB co-infected patients in Coastal South India. MJNHS. 2015;1(1):9-13.

Parrikar A, Lawande D, Cacodcar J. A study of HIV-TB co-infection and its determinants at a tertiary care hospital in Goa. 2020.

Ghiya R, Naik E, Casanas B, Izurieta R, Marfatia Y. Clinico-epidemiological profile of HIV/TB coinfected patients in Vadodara, Gujarat. Ind J Sexual Transmit Dis AIDS. 2009;30(1):10.

Deepak KG, Daivadanam M, Pradeepkumar AS, Mini GK, Thankappan KR, Nichter M. Smokeless tobacco use among patients with tuberculosis in Karnataka: the need for cessation services. National Med J India. 2012;25(3):142.

Mariappan VA, Sahu SK, Sarkar S, Kattimani S, Soundappan G. Smoked and smokeless tobacco use among pulmonary tuberculosis patients under RNTCP in urban Puducherry, India. Ind J Tuberculos. 2016;63(3):158-66.

Takhar RP, Mirdha K, Purohit G, Maan L, Bainara MK. Impact of HIV co-infection on clinical presentation in patients with TB and correlation of the findings with level of immune suppression. Tanaffos. 2018;17(3):188.

Patel AK, Thakrar SJ, Ghanchi FD. Clinical and laboratory profile of patients with TB/HIV coinfection: A case series of 50 patients. Lung India: Org Ind Chest Soci. 2011;28(2):93.

Swarooprani NB, Wadekar MD, Rajakumar S. Impact of CD4 Count on sputum smear for AFB in HIV-TB Co infection. Indian J Microbiol Res. 2016;3(2):126.

Banu Rekha VV, Balasubramanian R, Swaminathan S, Ramachandran R, Rahman F, Sundaram V, et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Ind J Med Res. 2007;126(Nov):452-8.

Bawri S, Ali S, Phukan C, Tayal B, Baruwa P. A study of sputum conversion in new smear positive pulmonary tuberculosis cases at the monthly intervals of 1st, 2nd & 3rd month under directly observed treatment, short course (dots) regimen. Lung India: Org Ind Chest Soci. 2008;25(3):118.

Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India. 2012;60(8):22-6.

Sara C, Elsa H, Baijayanti M, Lennartsdotter EM. Clinical correlates and drug resistance in HIV-infected and-uninfected pulmonary tuberculosis patients in South India. World J AIDS. 2016;6(3):87.

Swaminathan S, Padmapriyadarsini C, Sukumar B, Iliayas S, Kumar SR, Triveni C, et al. Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India. Clinical Infectious Diseases. 2008;46(6):946-9.

Jaryal A, Raina R, Sarkar M, Sharma A. Manifestations of tuberculosis in HIV/AIDS patients and its relationship with CD4 count. Lung India: Org Ind Chest Soci. 2011;28(4):263

Vijay S, Kumar P, Chauhan LS, Rao SV, Vaidyanathan P. Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South India. PLoS One. 2011;6(7):e21008.

Training modules (1-4) for programme managers & medical officers, National TB Elimination Programme Central TB Division, Ministry of Health & Family Welfare, Government of India, New Delhi, 2020. Available at: Accessed 21 June 2023.

Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Ind J Med Res. 2005;121(4):550-67.

Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Inter J Infect Dis. 2014;28:95-100.

Shastri S, Naik B, Shet A, Rewari B, De Costa A. TB treatment outcomes among TB-HIV co-infections in Karnataka, India: how do these compare with non-HIV tuberculosis outcomes in the province?. BMC public health. 2013;13(1):1-6.




How to Cite

Kadam, M. (2023). Impact of human immunodeficiency virus on category I pulmonary tuberculosis cases in a tertiary care hospital: a case control study. International Journal Of Community Medicine And Public Health, 10(9), 3249–3256.



Original Research Articles